Saptarsi M. Haldar, MD, is a Vice President of Research at Amgen, where he is Head of Cardiometabolic Discovery, based out of Amgen's South San Francisco campus. He is also a Visiting Professor at The Gladstone Institutes and University of California San Francisco (UCSF), where he remains active academically and clinically. He received his BS from Cornell University and MD from Johns Hopkins University School of Medicine. He completed an Internal Medicine residency at Johns Hopkins followed by a Fellowship in Cardiovascular Disease at Brigham and Women’s Hospital, Harvard Medical School. After training in the laboratory of Dr. Mukesh Jain, he was on faculty at Case Western Reserve University School of Medicine prior to joining Gladstone/UCSF. Dr. Haldar’s research group has uncovered novel gene regulatory signaling mechanisms that govern cardiovascular and metabolic homeostasis and has elucidated how these processes go awry in disease. His work has provided therapeutically relevant insights for a broad range of conditions such as heart failure, metabolic disorders, muscular dystrophy, and vascular disease. One major program in the laboratory centers on the discovery that a subset of chromatin co-activator proteins, such as BRD4 and TFIIH-kinase, are novel epigenetic regulators of cardiac homeostasis and heart failure pathogenesis. This work was the first to implicate chromatin reader proteins in cardiovascular biology and established the general principle that drugging the core transcription machinery was possible in heart failure. In addition to his university-based efforts, Dr. Haldar and his Gladstone colleagues are scientific co-founders of Tenaya Therapeutics, a San Francisco based company launched in 2016 whose goal is to develop novel therapies for heart failure. Dr. Haldar is a practicing general adult cardiologist at UCSF who is dedicated to teaching and mentoring, in the classroom, wards and laboratory settings. He was recruited to his executive leadership role at Amgen in August 2018.